{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Radiation+Safety&page=2",
    "query": {
      "condition": "Radiation Safety",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Radiation+Safety&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T11:38:57.359Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02324335",
      "title": "Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Neoplasms",
        "Mucositis"
      ],
      "interventions": [
        {
          "name": "Brilacidin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Innovation Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2014-08-14",
      "completion_date": "2017-11-22",
      "has_results": true,
      "last_update_posted_date": "2019-01-16",
      "last_synced_at": "2026-09-28T11:38:57.359Z",
      "location_count": 16,
      "location_summary": "Gilbert, Arizona • Lakeland, Florida • Columbus, Georgia + 13 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02324335"
    },
    {
      "nct_id": "NCT06802614",
      "title": "Efficacy and Safety Assessment of Experimental Bleaching Agents",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Tooth Discoloration",
        "Dentin Sensitivity",
        "Patient Satisfaction"
      ],
      "interventions": [
        {
          "name": "BLEACHING GEL A",
          "type": "DEVICE"
        },
        {
          "name": "5% NF_TiO2",
          "type": "DEVICE"
        },
        {
          "name": "BLEACHING GEL B",
          "type": "DEVICE"
        },
        {
          "name": "VISIBLE LIGHT IRRADIATION",
          "type": "RADIATION"
        },
        {
          "name": "Whiteness HP 35%",
          "type": "DEVICE"
        },
        {
          "name": "Whiteness HP Automixx 6%",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "RADIATION"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 240,
      "start_date": "2025-03-01",
      "completion_date": "2025-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-01-31",
      "last_synced_at": "2026-09-28T11:38:57.359Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06802614"
    },
    {
      "nct_id": "NCT00437372",
      "title": "Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Head and Neck Cancer",
        "Pelvic Cancer",
        "Nervous System Neoplasms",
        "Thoracic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Sunitinib",
          "type": "DRUG"
        },
        {
          "name": "External Beam Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2007-03",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2025-05-02",
      "last_synced_at": "2026-09-28T11:38:57.359Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00437372"
    },
    {
      "nct_id": "NCT01771679",
      "title": "Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Effect of Ultraviolet Radiation on Photoaged Skin",
        "Dermatologic Disorders"
      ],
      "interventions": [
        {
          "name": "Allogeneic Mesenchymal Bone Marrow Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Stemedica Cell Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 29,
      "start_date": "2015-07-01",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-10-31",
      "last_synced_at": "2026-09-28T11:38:57.359Z",
      "location_count": 2,
      "location_summary": "La Mesa, California • San Diego, California",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01771679"
    },
    {
      "nct_id": "NCT02542215",
      "title": "Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Oral Mucositis"
      ],
      "interventions": [
        {
          "name": "Cobiprostone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard Care - Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Standard Care - Radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Sucampo Pharma Americas, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2015-06",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2019-12-02",
      "last_synced_at": "2026-09-28T11:38:57.359Z",
      "location_count": 76,
      "location_summary": "Birmingham, Alabama • Peoria, Arizona • Yuma, Arizona + 72 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02542215"
    },
    {
      "nct_id": "NCT00923195",
      "title": "Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Skin Cancer"
      ],
      "interventions": [
        {
          "name": "MART-1: 26-35(27L) Peptide",
          "type": "DRUG"
        },
        {
          "name": "Montanide ISA 51 VG",
          "type": "DRUG"
        },
        {
          "name": "gp100:154-162 Peptide",
          "type": "DRUG"
        },
        {
          "name": "Radiation",
          "type": "PROCEDURE"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Anti-gp 100:154 TCR PBL",
          "type": "GENETIC"
        },
        {
          "name": "Anti-MART-1 F5 TCR PBL",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "GENETIC"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2008-12",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2015-10-28",
      "last_synced_at": "2026-09-28T11:38:57.359Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00923195"
    },
    {
      "nct_id": "NCT05926765",
      "title": "A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands"
      ],
      "interventions": [
        {
          "name": "AAV2-hAQP1 Concentration 1",
          "type": "GENETIC"
        },
        {
          "name": "AAV2-hAQP1 Concentration 2",
          "type": "GENETIC"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "AAV2-hAQP1 Concentration 3",
          "type": "GENETIC"
        },
        {
          "name": "AAV2-hAQP1 Concentration 4",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "MeiraGTx, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 290,
      "start_date": "2023-06-13",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-09-28T11:38:57.359Z",
      "location_count": 18,
      "location_summary": "Gilbert, Arizona • Duarte, California • Miami, Florida + 14 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05926765"
    },
    {
      "nct_id": "NCT01644669",
      "title": "Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Invasive Ductal Carcinoma",
        "Ductal Carcinoma in Situ"
      ],
      "interventions": [
        {
          "name": "Intra-operative Radiation Therapy - IORT",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Xoft, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "40 Years and older · Female only"
      },
      "enrollment_count": 1200,
      "start_date": "2012-05-08",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-01-31",
      "last_synced_at": "2026-09-28T11:38:57.359Z",
      "location_count": 22,
      "location_summary": "Tucson, Arizona • Duarte, California • Long Beach, California + 17 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01644669"
    },
    {
      "nct_id": "NCT04428203",
      "title": "Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer Recurrent",
        "Prostate Cancer",
        "Prostate Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Epidiolex Oral Liquid Product",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zin W Myint",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 21,
      "start_date": "2020-08-03",
      "completion_date": "2021-08-20",
      "has_results": true,
      "last_update_posted_date": "2025-03-05",
      "last_synced_at": "2026-09-28T11:38:57.359Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04428203"
    },
    {
      "nct_id": "NCT01871454",
      "title": "Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancers"
      ],
      "interventions": [
        {
          "name": "stereotactic ablative radiotherapy (SABR)",
          "type": "RADIATION"
        },
        {
          "name": "Pentoxifylline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2013-10",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2024-02-07",
      "last_synced_at": "2026-09-28T11:38:57.359Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01871454"
    }
  ]
}